While 4F-PCC rapidly supplies vitamin K-dependent procoagulant factors II, VII, IX, and X, Andexanet alfa is a modified Factor Xa decoy molecule engineered to outcompete endogenous Factor Xa for FXaI binding.81 While andexanet alfa offers specific, targeted FXaI reversal compared to 4F-PCCs, a recent meta-analysis showed similar outcomes pertaining to anticoagulant reversal, mortality, and thromboembolic rates between the 2 agents,82 for patients with intracranial hemorrhage. The gene discussed is F10; the disease is intracranial hemorrhage.